Elite Pharma Inc (ELTP) 0.1450 $ELTP FDA Issues Complete

New Post Public Reply Private Reply Replies (0) Message Board

Jul 27, 2016 at 12:03 PM

Elite Pharma Inc (ELTP) 0.1450 $ELTP

FDA Issues Complete Response Letter for SequestOx(TM) New Drug Application
GlobeNewswire - Fri Jul 15, 4:06PM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced that the U.S. Food and Drug Administration (the "FDA"

has issued a Complete Response Letter (the "CRL"

regarding the New Drug Application (the "NDA"

for SequestOx(TM) (oxycodone hydrochloride and naltrexone hydrochloride), Elite's investigational abuse-deterrent opioid candidate for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2016 and Provides Conference Call Information
GlobeNewswire - Wed Jun 15, 3:19PM CDT
Revenues Increased 150%

Elite Pharmaceuticals to Present SequestOx(TM) Data at the American Pain Society 35th Annual Scientific Meeting
GlobeNewswire - Mon May 09, 6:30AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today it will present data for SequestOx(TM) (ELI-200) at the American Pain Society 35 Annual Scientific Meeting being held in Austin, Texas, USA, May 11 - 14, 2016. The abstract, is entitled Pharmacodynamic data assessing the abuse potential of a novel abuse deterrent oxycodone formulation (ELI-200) compared to oxycodone immediate release, oral intact ELI-200, and placebo in healthy, non-dependent recreational opioid users following intranasal administration.

Elite Pharmaceuticals Appoints Davis S. Caskey to Its Board of Directors
GlobeNewswire - Wed May 04, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today that its Board of Directors has appointed Davis S. Caskey to its board effective April 28, 2016.

Elite Pharmaceuticals Announces Changes to their Board of Directors
GlobeNewswire - Tue Apr 12, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today that its Board of Directors has appointed Eugene Pfeifer to its board effective April 7, 2016. At the same meeting, the Board accepted the resignation of Jeenarine Narine.

Increasing Demand in Graphene 3-D Printing Technology Company: Graphene 3D Lab
ACCESSWIRE - Thu Mar 24, 7:32AM CDT
MIAMI, FL / ACCESSWIRE / March 24, 2016 / EmergingGrowth.com - Graphene 3D Lab (OTCQB: GPHBF) wholly owned subsidiary Graphene Laboratories, Inc. offers over 100 Graphene and related products to more than 10,000 customers worldwide including every Fortune 500 tech company and major research university.
NETE: 2.16 (+0.03), GS: 160.57 (-0.59), CLF: 7.87 (-0.15), HPQ: 14.06 (-0.12)

Penny Stocks to Buy on St. Patrick's Day... If You So Choose
ACCESSWIRE - Thu Mar 17, 10:54AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 17, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. HTBX, CLF, BTU, and ELTP have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, Nasdaq, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
HTBX: 0.72 (+0.01), BTU: 2.07 (unch), CLF: 7.87 (-0.15)

Elite Announces U.S. FDA Priority Review Designation for SequestOx(TM) NDA
GlobeNewswire - Thu Mar 17, 6:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced that the New Drug Application (NDA) for SequestOX(ELI-200), Elite's lead opioid abuse-deterrent candidate for the management of moderate to severe pain where the use of an opioid analgesic is appropriate, has been accepted and granted priority review by the United States Food and Drug Administration ("FDA"

. The FDA has set a target action date under the Prescription Drug User Fee Act ("PDUFA"

of July 14, 2016.

What are Investors Looking at - Research on WorldFlix, Elite Pharmaceuticals, South32 and Koninklijke DSM
ACCESSWIRE - Tue Mar 08, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / March 8, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: WorldFlix Inc. (OTC: WRFX), Elite Pharmaceuticals Inc. (OTC: ELTP), South32 Ltd. (OTC: SOUHY) and Koninklijke DSM NV (OTC: RDSMY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

$200 Million Order, Industrial Commodities Co. Strikes Gold in Iron Ore
ACCESSWIRE - Wed Feb 10, 7:31AM CST
MIAMI, FL / ACCESSWIRE / February 10, 2016 / $200 Million Order, Industrial Commodities Co. Strikes Gold in Iron Ore. CD International Enterprises, Inc. (OTCPK: CDII), a U.S.-based company that sources industrial commodities just announced that a $200 million order, over a 24-month period was placed with its wholly owned subsidiary Capital Resources Management Corporation.
CLF: 7.87 (-0.15)

Elite Pharmaceuticals generates higher consolidated revenues of USD2.2m for Q3 fiscal 2016
M2 - Wed Feb 10, 4:58AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) stated on Tuesday that it recorded consolidated revenues of USD2.2m for the quarter ended 31 December 2015, the third quarter of its 2016 fiscal year.

Elite Pharmaceuticals, Inc. Reports Strong Growth for Third Quarter of Fiscal Year 2016
GlobeNewswire - Tue Feb 09, 3:32PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP), announced results for the quarter ended December 31, 2015, the third quarter of its 2016 fiscal year.

Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2016 Financial Results on February 10, 2016
GlobeNewswire - Fri Feb 05, 11:43AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its third quarter financial results will be released on Tuesday, February 9, 2016. Following the announcement, Elite's management will host a live conference call on Wednesday, February 10 at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update. Company executives will conduct a question and answer session following their remarks. Shareholders may submit questions for management in advance of the call.

Analyst Insights Behind Price Movement - Analyst Research on CD International Enterprises, Elite Pharmaceuticals, Anglo American and Pilot Gold
ACCESSWIRE - Mon Feb 01, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CD International Enterprises Inc. (OTC: CDII), Elite Pharmaceuticals Inc. (OTC: ELTP), Anglo American PLC (OTC: NGLOY) and Pilot Gold Inc. (OTC: PLGTF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Traders Look to Upside - Analyst Research on SandRidge Energy, Elite Pharmaceuticals, Dyadic International and Accretive Health
ACCESSWIRE - Thu Jan 21, 8:34AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SandRidge Energy Inc. (OTC: SDOC), Elite Pharmaceuticals Inc. (OTC: ELTP), Dyadic International Inc. (OTC: DYAI) and Accretive Health Inc. (OTC: ACHI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
SD: 0.15 (-0.02)

Elite Pharmaceuticals awarded waiver fee for ELI-200 NDA under section 736(d)(1)(E) of the Federal Food, Drug and Cosmetic Act
M2 - Fri Jan 15, 5:10AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) stated on Thursday that it has received a waiver of the application fee required for the filing of a New Drug Application (NDA) for ELI-200 from the US Food and Drug Administration (FDA).

Elite Pharmaceuticals reports changes in board
M2 - Thu Jan 14, 6:27AM CST
Elite Pharmaceuticals (OTCBB:ELTP) said on Wednesday that Jerry Treppel has stepped down as its chairman and as a member of the board of directors with effect from 11 January 2016, to pursue other opportunities.

FDA Approves Waiver of NDA Filing Fee for Elite Pharmaceuticals
GlobeNewswire - Wed Jan 13, 3:52PM CST
The United State Food and Drug Administration ("FDA"

granted Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) a waiver of the application fee required for the filing of a New Drug Application (NDA). Under section 736(d)(1)(E) of the Federal Food, Drug and Cosmetic Act the FDA may grant a waiver of the $2,335,200 NDA application fee for the first human drug application that a small business submits for review.

Nasrat Hakim Named Chairman of Board of Directors for Elite Pharmaceuticals
GlobeNewswire - Wed Jan 13, 8:25AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced that Jerry Treppel has resigned as the Company's Chairman and as a member of the Board of Directors, effective January 11, 2016, to pursue other opportunities.

Five Small Cap Stocks Experiencing Huge Growth Potential
ACCESSWIRE - Fri Dec 11, 7:18AM CST
DELRAY BEACH, FL / ACCESSWIRE / December 11, 2015 / In today's quickly evolving market, small cap stocks increasingly profile as a viable investment for those with a higher risk tolerance. While the global market stirs, newer, smaller companies continue to claim larger portions of industry shares, and surprising names begin to surface as possible leaders in their respective fields.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ultrabench Revolutionizes AI Model Comparison Game

Breaking Down the Messy AI Model Landscape Ultrabench.ai is here to drag AI model comparison out of the dark ages. Picture this: 309 AI models, ranked against a whopping 530 benchmarks, all served up on one plate. If you’re navigating the AI jungle, you’ll realize how Ultrabench is no small fish in this vast ocean. Consolidating Where Others Have Scattered There's a...

Varda Space's Dual Launch Signals Orbital Ambitions

It's not every day you see two commercial rockets heading to orbit on the same ride, but that's precisely what Varda Space Industries just pulled off. With the W-8 and W-9 vehicles blasting off together, Varda is positioning itself for a leap in orbital operations. They've hitched a ride aboard SpaceX's Transporter-18 mission, and this is more than just a double...

Managed Connectivity: Key to Modern Multifamily Living

Connectivity Runs the Modern Show Imagine moving into a shiny new apartment, where the biggest hassle isn't unpacking boxes but ensuring your gadgets get online smoothly. That's the reality of today's multifamily living, where the internet is more than a utility—it's the backbone of modern life. And if you think it's just about offering internet access, you're missing...

SaponiQ Reinvents Body Care with Botanical Soap Bars

Breaking Through with Simple Innovation I'll be the first to say it's not every day you hear about a soap company trying to shake things up in body care like it’s a tech startup, but here’s SaponiQ taking a wild swing at it with their lineup of botanical cleansing bars. These things are whipped up in their own U.S.-based facility using some fancy cold-process...

Nelson-Jameson Boosts Cold Storage in California Move

An Icy Boost for the West Coast Dairy Player Every now and then, a company gets its cold storage game just right. Nelson-Jameson has added fresh muscle to its Turlock facility in California, making waves with serious logistical upgrades. The company's dogged pursuit of better operational efficiency in dairy processing isn't just about bragging rights. It's plain old good...

Athlete Threats: Public Info Fuels Security Risks

Public Exposure: The New Athlete Achilles' Heel Imagine sitting on millions while living in a glass house. That's the kind of predicament today's athletes find themselves in, thanks to the treasure trove of public information spilling their personal lives all over the internet. According to the latest Hush Intelligence Athlete Threat Report 2026, this very exposure has...

Haystack MRD Shines in Colorectal Cancer Trials

A New Dawn in Cancer Detection Just when you think you've seen it all in cancer diagnostics, Haystack MRD® pops up like a fresh tulip in spring. And listen, this ain't just fluff—the results from the DYNAMIC trials are a pretty compelling love letter to the power of liquid biopsy. With 100% specificity and sensitivity hitting a whopping 83.3% over five years, it’s...

Karen Love's Retirement Marks End of an Era for TACHP

A Legacy Not Just Built, But Carved in Stone In the world of healthcare, folks like Karen Love don’t come around too often. She's stepping down from her post as President and CEO of Cook Children's Health Plan this month, and it feels like the end of a chapter for the Texas Association of Community Health Plans (TACHP). Love wasn't just an executive; she was a mover and...

Comparent Unveils Key Insights with Top 100 List

The Ebb and Flow of Vacation Rental Giants Ever noticed how some industries just sneak up and suddenly transform landscapes? Vacation rental management is one of those sneaky offenders. At the forefront of keeping tabs on this bustling sector, Comparent just dropped a meaty second annual roster—the Comparent 100—showcasing the biggest players flexing their muscles in...

Texas A&M-San Antonio's Research Expansion Momentum

Texas A&M-San Antonio's Rising Research Ambitions A rainy day in San Antonio and Texas A&M University-San Antonio seems to have set the stage for more than just another semester of record enrollment. They’ve just rolled in with an exhilarating $8 million in external grants this fiscal year, more than doubling last year’s haul of $3.6 million, in a bid to push their...